Latest Oligodendroglioma Stories

A new vaccine added to standard therapy appears to offer a survival advantage for patients suffering from glioblastoma (GBM), the most deadly form of brain cancer, according to a study from researchers at Duke University Medical Center and The University of Texas MD Anderson Cancer Center.The vaccine also knocks out a troublesome growth factor that characterizes the most aggressive form of the disease."About a third of all glioblastomas are fueled by a very aggressive cancer gene, called...

CHICAGO, June 5 /PRNewswire/ -- Data from the first phase III clinical trial of NovoCure's NovoTTF device for treatment of patients with recurrent glioblastoma (GBM) were presented today as a late breaking abstract during the Neuro-Oncology session at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. Study results show that NovoTTF, a novel, non-invasive, portable medical device, may be as or more effective than the best available chemotherapies for GBM, but...

Researchers have identified an important cancer gene that could lead to more effective drugs being developed to fight pediatric high grade glioma, a disease which currently has a poor prognosis.The discovery, published in the Journal of Clinical Oncology, was one of a number of significant genetic differences found between the adult and youth form of the disease. Gliomas are the most common brain tumor in children.Clinicians and scientists at The Institute of Cancer Research (ICR) and The...

MALVERN, Pa., Oct. 26 /PRNewswire/ -- Ascenta Therapeutics announced today that encouraging results from a Phase I dose-escalation study of two combination therapy regimens containing AT-101, an oral, pan-Bcl-2 inhibitor, in patients with the most malignant type of brain tumor, were described in an oral presentation at the 2009 Joint Meeting of the Society for NeuroOncology (SNO) and AANS/CNS Section on Tumors in New Orleans, Louisiana (Concurrent Session VI: Radiation Oncology, October 23,...

Chemotherapy alone is just as effective as radiation / New positive prognostic factor foundInitial chemotherapy alone after surgery is just as successful as initial radiation therapy for patients from whom a very malignant brain tumor (anaplastic glioma) was removed. With this treatment, the patients survive on average > 30 months without a recurrence. A study conducted by the Neurooncology Working Group of the German Cancer Society led by researchers from Heidelberg and Zürich showed...

BOSTON, Mass. and TUSTIN, Calif., Sept. 2 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM) today reported that clinical investigators are presenting interim Phase II data showing that its brain cancer agent Cotara(R) appeared well tolerated and demonstrated encouraging signs of efficacy in patients with glioblastoma multiforme (GBM), the deadliest form of brain cancer. The data from an ongoing Phase II study of Cotara in patients with recurrent GBM is being...

A U.S. study indicates the use of the drug Avastin to treat a subgroup of recurrent brain tumors is safe and effective at delaying tumor progression. The retrospective study conducted at the Seattle Cancer Care Alliance involved 22 patients suffering from a recurrent malignant glioma known as alkylator-refractory anaplastic oligodendroglioma, for which there is no existing standard therapy. Avastin, known generically as bevacizumab, is the first approved therapy designed to inhibit...

The final results of a clinical trial show adding chemotherapy to radiotherapy treatment for brain tumors can extend a patient's survival for up to five years.Researchers focused their study on the most common and aggressive brain tumor, glioblastoma.  For over 30 years, post-operative radiotherapy was the standard treatment, but only offered modest survival benefits -- about nine months. In the clinical trial, scientists gave patients the chemotherapy drug temozolomide in combination with...

German and Swiss scientists say they have used the combination of two drugs to achieve a substantial improvement in the treatment of certain brain tumors. The researchers led by Professor Dr. Ulrich Herrlinger of the University of Bonn treated 39 patients who had been diagnosed with a gliablastoma. The patients -- treated with a combination of temozolomide and lomustine -- survived on average 23.1 months, while with the standard therapy the mean would have been 14.6 months, the researchers...

A Drug That Improves Survival, When Added to Temodar/Temodal, Would Earn a 65 Percent Patient Share in the U.S. and a 30 Percent Patient Share in Europe in Newly Diagnosed Glioblastoma Multiforme, According to a New Report from Decision Resources WALTHAM, Mass., March 9 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that surveyed oncologists identify a therapy's effect on overall survival as the...